Condition
Vasodilatory Shock
Total Trials
7
Recruiting
1
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
43%
3 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 2 (1)
P 3 (1)
P 4 (2)
Trial Status
Completed2
Enrolling By Invitation1
Active Not Recruiting1
Terminated1
Unknown1
Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT07568275Early Phase 1Active Not Recruiting
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
NCT05824767Phase 4Completed
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
NCT07212686Phase 4Enrolling By InvitationPrimary
Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension
NCT06953297Completed
Vasopressin Use in Septic Shock From Türkiye
NCT06351150Phase 3RecruitingPrimary
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT03378466Phase 2Terminated
Heparin Anticoagulation in Septic Shock
NCT03245528Unknown
Expanded Access for LJPC-501
Showing all 7 trials